123 related articles for article (PubMed ID: 10566061)
41. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
Seccia TM; Belloni AS; Guidolin D; Sticchi D; Nussdorfer GG; Pessina AC; Rossi GP
J Hypertens; 2006 Jul; 24(7):1419-27. PubMed ID: 16794493
[TBL] [Abstract][Full Text] [Related]
42. AE 941--Neovastat.
Drugs R D; 1999 Feb; 1(2):135-6. PubMed ID: 10566006
[No Abstract] [Full Text] [Related]
43. Disposition and metabolism of the angiotensin-converting enzyme inhibitor [4S-[4 alpha, 7 alpha, (R*), 12b beta]]-7-[S-(1-ethoxycarbonyl-3- phenylpropyl)amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo- pyrido[2,1-a][2]benzazepine-4-carboxylic acid in monkeys and dogs.
Cheng H; Stuhler JD; Dorrbecker BR; Gordon WP
Drug Metab Dispos; 1991; 19(1):212-7. PubMed ID: 1673401
[TBL] [Abstract][Full Text] [Related]
44. Vasopeptidase inhibition as a new concept in antihypertensive therapy.
Dendorfer A; Dominiak P
Kidney Blood Press Res; 2000; 23(3-5):178-9. PubMed ID: 11031714
[No Abstract] [Full Text] [Related]
45. Effects of benazepril, an angiotensin-converting enzyme inhibitor, combined with CGS 35066, a selective endothelin-converting enzyme inhibitor, on arterial blood pressure in normotensive and spontaneously hypertensive rats.
Battistini B; Ayach B; Molez S; Blouin A; Jeng AY
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():363S-366S. PubMed ID: 12193123
[TBL] [Abstract][Full Text] [Related]
46. [Omapatrilat--new drug for patients with hypertension and heart failure].
Dzielska-Olczak M
Pol Merkur Lekarski; 2005 Oct; 19(112):556-8. PubMed ID: 16379325
[TBL] [Abstract][Full Text] [Related]
47. Antihypertensive action of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride in hypertensive rat models.
Tanaka M; Yamamoto S; Nakao K; Inukai T; Ogawa N; Katsumura H; Ohara N; Shukunobe K; Ono H
Arzneimittelforschung; 1991 Jun; 41(6):608-12. PubMed ID: 1930348
[TBL] [Abstract][Full Text] [Related]
48. [Heart failure and vasopeptidase inhibitors].
Bareiss P; Ohlmann P; Roul G
Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):51-3. PubMed ID: 11933558
[TBL] [Abstract][Full Text] [Related]
49. J 104132. L 753037.
Drugs R D; 1999 Jul; 2(1):26-7. PubMed ID: 10610293
[No Abstract] [Full Text] [Related]
50. [The clinical pharmacology of angiotensin II antagonists].
Arabidze GG; Novikova LS
Farmakol Toksikol; 1990; 53(2):80-6. PubMed ID: 2369961
[TBL] [Abstract][Full Text] [Related]
51. Rapid reversal of angiotensin I-induced contractions in rat carotid arteries after acute and chronic treatment with the angiotensin-converting enzyme inhibitor, 3-[(5-amino-1-carboxy-1S-pentyl)amino]2,3,4,5-tetrahydro-2-oxo- 3S-1H-1-benzazepena-1-acetic acid (CGS 16617).
Weiss GB; Sturm B; Levens NR
J Pharmacol Exp Ther; 1993 Dec; 267(3):1407-13. PubMed ID: 8263802
[TBL] [Abstract][Full Text] [Related]
52. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure.
Northridge DB; Currie PF; Newby DE; McMurray JJ; Ford M; Boon NA; Dargie HJ
Eur J Heart Fail; 1999 Mar; 1(1):67-72. PubMed ID: 10937982
[TBL] [Abstract][Full Text] [Related]
53. Development of a new benazepril hydrochloride chewable tablet and evaluation of its bioequivalence for treatment of heart failure in dogs.
Qian M; Chen T; Zhou D; Zhang Z; Zhang Q; Tang S; Xiao X
J Vet Pharmacol Ther; 2016 Feb; 39(1):98-101. PubMed ID: 26228576
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers.
Emmons GT; Argenti R; Martin LL; Martin NE; Jensen BK
J Clin Pharmacol; 2004 Aug; 44(8):901-5. PubMed ID: 15286094
[TBL] [Abstract][Full Text] [Related]
55. Angiotensin converting enzyme inhibitors. Pharmacological and physiological background for cardiovascular treatment.
Jerie P
Cor Vasa; 1992; 34(1):31-66. PubMed ID: 1288942
[No Abstract] [Full Text] [Related]
56. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
[TBL] [Abstract][Full Text] [Related]
57. [Cardiovascular pharmacology (IX). Angiotensin-converting enzyme inhibitors in hypertension and heart failure].
de Teresa E; Espinosa JS; Gómez Doblas JJ
Rev Esp Cardiol; 1995 Feb; 48(2):128-41. PubMed ID: 7886264
[No Abstract] [Full Text] [Related]
58. [Vasopeptidase inhibition: a new mechanism of action--a new antihypertensive drug].
Waeber B
Praxis (Bern 1994); 2000 Apr; 89(16):649-53. PubMed ID: 10823018
[TBL] [Abstract][Full Text] [Related]
59. Sampatrilat Shire.
Allikmets K
Curr Opin Investig Drugs; 2002 Apr; 3(4):578-81. PubMed ID: 12090727
[TBL] [Abstract][Full Text] [Related]
60. [Drugs in cardiology. Angiotensin-converting enzyme inhibitors].
Garrote C; Alegría E
Enferm Intensiva; 1995; 6(2):74-6. PubMed ID: 7493281
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
